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Fetotoxic Effects of Mono-2-ethylhexyl
Phthalate (MEHP) in Mice
by Isao Tomita,* Yoshiyuki Nakamura,* Yasuoki Yagi,*t and
Kiyosi Tutikawat
Mono(2-ethylhexyl) phthalate (MEHP), one ofthe main metabolites ofdi(2-ethylhexyl) phthalate (DEHP),
exerted embryo/fetotoxic effects similar to those of DEHP at lower doses. Oral administration ofMEHP (1
mL/kg) to the mice of8 days gestation resulted in less than 32% oflive fetuses, all ofwhich were deformed.
When DEHP (10 mL/kg) was given to the pregnant mice of8 days gestation, approximately 0.03% and 0.003%
of the administered dose was found in fetuses as DEHP and MEHP, respectively, after 12 hr.
The presence ofthe MEHP in fetuses is probably due to the transplacental crossing ofthe MEHP formed
in the maternal body, since the fetuses of mice up to day 9 of pregnancy showed no hydrolytic activity of
DEHP to MEHP. Crossing of MEHP through the placenta was proven by an experiment in which MEHP
was administered in pregnant mice.
A single injection of MEHP (25 or 50 mg/kg), but not DEHP (500 mg/kg) into pregnant mice, induced a
significantly high incidence of somatic mutations in the coat hair of offspring of mice (KYG, 9 x PW,d;
C57BL/6Crj, 9 x PW, 6). All these data suggest that MEHP could be responsible for the embryotoxic/
fetotoxic effects observed with DEHP.
Introduction
A number of investigators have demonstrated that
administration of di(2-ethylhexyl) phthalate (DEHP) in-
duced embryotoxic fetotoxic effects in rats (1,2) and mice
(3-5). The effects depend on the route, dose, and time
when DEHP was given; the oral administration ofDEHP
(10mL/kg) tomice onday 7 or8ofgestation, forexample,
resulted in ahighincidence ofdead ormalformed fetuses.
However, treatment of the mice before or after this sen-
sitive stage,e.g., day 6, 9, or 10 ofgestation, resulted in
fewer defective fetuses even when higher doses ofDEHP
were administered (4).
Similarand moretoxiceffects havebeenobservedwhen
mono(2-ethylhexyl) phthalate (MEHP), an intermediary
metabolite ofDEHP, wasgivenorallytomice. Theadmin-
istration ofMEHP (1 mL/kg) to mice ofday8 ofgestation
resulted inlessthan 32% live fetuses, all ofwhich showed
gross and skeletal abnormalities (4).
Thepresentinvestigation wasundertakentodetermine
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whether the embryotoxic/fetotoxic effects of DEHP are
related to the metabolic formation of MEHP in the ma-
ternal body and/or in fetuses. DEHP is known to be
hydrolyzed to MEHP and 2-ethylhexanol (6-8). The hy-
drolysis is catalyzed by pancreatic lipase (9), acid and
alkaline esterases in intestinal mucosa (10,11), plasma
(12), and liver (6). Tissue distribution ofMEHP afterthe
oral administration of DEHP (or MEHP) has been re-
ported by several investigators in pregnant or nonpreg-
nant rats (7,13,14). The study with 14C-DEHP in preg-
nant Sprague-Dawley rats indicated that most tissues
andfluids, includingmaternalblood, fetaltissue, amniotic
fluid, and placenta, all contained radiolabel (15). The con-
centration of MEHP, however, is not clear in this study.
We have examined the concentrations ofboth MEHP and
DEHP in tissues including fetuses by giving DEHP (or
MEHP) to the mice (ddY-SLC, 9 x CBA, d) on dif-
ferent days of pregnancy Both DEHP and MEHP were
found in fetuses, and their concentrations varied de-
pending on the period of pregnancy
In our previous paper (16), we demonstrated that
MEHP induced genotoxic effects in microbial and mam-
malian assay systems. The IP administration of MEHP
to the KYG or C57BL/6NCrj female mice mated with a
PW male resulted in a significantly higher incidence of
the appearance ofrecessive spots.
These data may suggest that MEHP as a metabolite
of DEHP is acting as a toxic principle for DEHPTOMITA ET AL.
Experimental
Virgin mice of the ddY-SLC (SPF) strain (Shizuoka
Experimental Animal Corp.) weighing 27-28 g (8-9
weeks old) were keptin a roomat25 + 20 C withhumidity
of50 + 5% for 1 week, after which they were mated with
mice of the CBA strain (National Institute of Genetics).
A laboratory diet (Funahashi Fann Co.) and tap water
were provided ad libitum.
MEHP was obtained from the method ofKenyon (17).
The crude materials were purified through a silica gel
(Wakogel) column (50 mm x 300 mm) by eluting with
chloroform. The material showed one spot on aluminum-
TLC coated with silica-gel 60F 254. It revealed a single
peak in ECD-GLC on a column packed with 1.5% OV-1.
MEHP was dissolved in olive oil and given to mice in
a single oral dose of 0.1, 0.5, or 1.0 mL/kg on day 7, 8,
or 9 of gestation. Body weight changes were recorded
daily for 18 days after gestation. The animals were then
sacrificed bydislocating the vertebrae. Theuterine horns
and ovaries were exposed to count the number of im-
plantations and live fetuses. Malformations (gross and
skeletal) and body weight were noted for all live fetuses.
MEHP was determined by ECD-GLC with diazome-
thane as follows: N2 gas was passed through tube A
containing diethyl ether (10 mL) and tube B containing
diethyleneglycol monoethyl ether (10 mL), 5 KOH pellets
in 2 mL water and 10% diethyl ether solution ofp-tolu-
enesulfonyl-N-methyl-N-nitrosamide, and was intro-
duced to tube C containing MEHP in diethyl ether (5
mL). The methylated MEHP (MeEHP) was passed
through a Florisil column containing 2-2.5% water and
eluted by 4% diethyl ether-n-hexane (200 mL). The 20%
diethyl ether-n-hexane eluate was used for MeEHP
analysis and DIBP (diisobutyl phthalate) was used as a
reference compound. The analytical method of the
MeEHP employed is essentially the same as that of
DEHP and other phthalic acid esters (18). When mouse
tissue containing MEHP and DEHP was used, it was
homogenized with four volumes of 0.25 M sucrose and
acidifiedwith4 N sulfuricacidfollowedbytwoextractions
with diethyl ether (20 mL). The diethyl ether extract
was then methylated as described above and analyzed by
ECD-GLC.
Radioactivity determination of mouse tissue after the
oraladministrationof14C-labeled DEHP (10mL/kg - 1.26
,uCi/mL) to 8th day gestation mice was carried out as
follows: mouse tissue which was homogenized with four
volumes of0.25 M sucrose and acidified with 4 N sulfuric
acid was extracted three times with diethyl ether (10
mL). The ether extract was then concentrated and ap-
plied to TLC (Kiesel gel 60F 254). After it was developed
with a solventmixture ofchloroform:methanol:acetic acid
= 147:7:2, the spots correspondingto DEHP (Rf = 0.93)
and MEHP (Rf = 0.46) were scraped and extracted with
chloroform. The radioactivity was determined by liquid
scintillation counting. Carbonyl (7-14C)-labeled DEHP
was synthesized according to the method ofWilliams et
al. (19).
The hydrolysis of DEHP to MEHP in mouse tissue
homogenate was performed by incubating a mixture of
0.5 mM DEHP (0.1 mL) in 0.1 M Tris-HCl buffer (pH
8.0, 0.2) and tissue homogenate (0.1 mL) at 37°C for 30
min. The MEHP formed was then extracted with 6 mL
of n-hexane-ethanol-3 N sulfuric acid mixture
(300:200;1), and the n-hexane layer (2 mL) was reacted
with Rhodamine 6G reagent (1 mL) according to the
method of Hirayama et al. (20). The absorbancy at 514
nm was read by the Hitachi spectrophtometer (Model
100-60). The hydrolysis of palmitic acid ethyl ester for
the hydrolytic activity determination was conducted in
the same manner as described for that of DEHP The
hydrolytic activity of mouse tissue homogenate was ex-
pressed as an absorbancy reading at 514 nm/mg protein.
The protein concentration was determined according to
the method of Lowry et al. (21). The mammalian spot
test using pregnant mice (KYG or C57BL/6NCrj mated
with PWmales) was conducted accordingto Russell (22).
DEHP or MEHP, dissolved in olive oil, was given to the
mice on the 10.5th day ofgestation and the appearance
ofwhite midventral and recessive spots in the coat ofthe
F1 mice was observed. The genotype of the embryos in
Table 1. Fetotoxic effects of MEHP on mice.
Dose Number of dead fetusesb Numbers of Average body
Day of administered, Number of Number of abnormalitiesc weight of
Groups gestation orally, mL/kg implantationsa Early death Late death live fetusesb Gross Skeletal fetuses
Untreated
control - - 56(5) 0 0 56(100) 0 0 1.41 ± 0.06
Olive oil 7 10.0 31(4) 0 0 31(100) 0 0 1.47 ± 0.06
MEHP 7 0.1 57(6) 8(14.0) 2(3.5) 47(82.5) 1(2.1) 3(6.4) 1.36 + 0.09 *
1.0 27(4) 17(63.0) 5(18.5) 5(18.5) 0 0 1.28 +0.09 *
8 0.1 64(8) 1(1.6) 2(3.1) 61(95.3) 4(6.6) 11(18.1) 1.40 ± 0.08
0.5 44(5) 1(2.3) 7(15.9) 36(81.8) 4(11.1) 7(19.4) 1.34 ± 0.11 *
1.0 22(2) 1(4.5) 14(63.6) 7(31.8) 7(100) 7(100) 1.02 0.02 *
9 1.0 30(3) 2(6.7) 1(3.3) 27(90.0) 8(29.6) 0 1.20 0.09 *
aValues in parentheses are numbers of pregnant mice used.
bNumbers in parentheses indicate percent dead or live fetuses based on total numbers ofimplantations.
'Numbers in parentheses indicate percent abnormalities based on total numbers of live fetuses.
*Significantly different from untreated controls at 99% level (p <0.01).
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Table 2. Distribution of DEHP in pregnant mice after the oral administration of DEHP on day 8 of gestation.
Groups Distribution of DEHP, ,ug/g of tissue a,b
Time after DEHP Number of Maternal tissues
administration, hr pregnant mice Liver Kidney Pancreas Bloodc Fetal tissue
0d 6 1.5 ± 0.3 3.0 ± 0.9 24.0 ± 10.6 <0.1 6.2 ± 2.0
(0.9 ± 0.2) (0.4 ± 0.1) (0.8 ± 0.3) (3.9 ± 2.1) (0.4 ± 0.1)
1 7 1060 ± 538 112 ± 47.3 3660 ± 2340 3.9 ± 2.1 274 120
(809 ± 277) (12.7 ± 5.4) (218 ± 140) (3.3 ± 1.8) (17.3 ± 9.0)
3 6 1480 ± 620 58.6 ± 28.4 11100 ± 5680 <0.1 522 291
(726 + 317) (6.8 ± 3.5) (343 ± 212) (22.8 ± 12.0)
12 5 1260 803 144 ± 83.4 4910 ± 3320 <0.1 426 290
(662 ± 416) (17.9 ± 10.3) (249 ± 169) (32.5 ± 19.8)
aEach value represents the mean ± SE.
bNumbers in parentheses representmg%o of administered DEHP.
CTotal blood volume of a mouse was assumed to be 8.5% of its body weight.
dUntreated control.
KYG x PW were ala B/b CP/cchp D/d sIS, while those MEHP in pregnant mice (8th day of gestation) when
in C57BL/6NCrj x PW were a/a B/b CP/cchp D/d. DEHP was given orally (10 mL/kg). The distribution of
Results DEHP and MEHP are expressed as micrograms per
gram of tissue weight and milligram-percentage of the
As shown in Table 1, the incidence of death and mal- dose administered. Though DEHP in the blood was min-
formation of fetuses caused by MEHP was dose- and imal, it was detected in the liver, kidney, pancreas, and
time-dependent. At a dosage of 0.1 mL, the highest in- fetal tissue. The highest concentrations of both DEHP
cidence offetal death (81%) was observed among mice in and MEHP were observed in the pancreas. The concen-
which MEHP was given on day 7 ofgestation, while the tration ofDEHP in fetal tissue increased with time after
incidences were 68% and 10% when MEHP was admin- its administration; the amounts were 522 ,ug/g (22.8 mg-
istered on day 8 and 9 respectively. As for the gross and %) and 426 ,ug/g (32.5 mg-%), 3 and 12 hr, respectively,
skeletal abnormalities, all live fetuses were malformed after DEHP administration. MEHP was also detected
when MEHPwasgiven onthe 8th dayofgestation, while in fetuses. The level of MEHP in fetal tissue was ap-
alowerincidence ofmalformation orno malformation was proximately 1% that of DEHP and corresponded to 4.6
observed on administration of MEHP on day 7 or 9 of ,ug/g tissue weight 12 hr after DEHP administration.
gestation. The results of the time dependence closely The presence of DEHP and MEHP in fetuses was con-
resembles those ofDEHP administration. Furthermore, firmed by an experiment with 14C-DEHPR The total
the data on day 8 ofgestation suggested thatteratogenic amounts of DEHP and MEHP detected by ECD-GLC
effects of MEHP are related to the dose administered and by the method of radioactivity determination were
as was previously seen in DEHP: the higher the dose, almost same (data not shown).
the larger the numbers of malformed fetuses observed. The next experiment was performed to study the ex-
Average body weights of most live fetuses in MEHP- tent to which the concentration of DEHP and MEHP
treated mice were significantly lower than that of the DEHP administration. Figure 1 shows the fluctuation of
control group, regardless ofthe day of administration. DEHP and MEHP in tissue 1 hr after the oral admin-
Tables 2 and 3 show the distribution of DEHP and istration of DEHP (10 mg/kg) or MEHP (1 mg/kg) to
could be altered according to the gestation period for pregnant and nonpregnant mice. The concentration of
Table 3. Distribution of MEHP in pregnant mice after the oral administration of DEHP on day 8 of gestation.
Groups Distribution of DEHP, ,ug/g of tissue a,b
Time after DEHP Number of Maternal tissues
administration, hr pregnant mice Liver Kidney Pancreas Bloodc Fetal tissue
od 6 1.4 ± 0.9c 1.0 ± 0.6 1.5 ± 0.6 <0.1 1.2 ± 0.4
(1.1 ± 0.7)d (0.3 ± 0.1) (0.1 ± 0.0) (0.1 ± 0.0)
1 7 29.1±7.7 6.8±2.7 381±142 83.8±12.0 4.3±1.1
(20.2 ± 5.6) (2.0 ± 0.8) (30.6 ± 11.0) (71.8 ± 10.3) (0.3 ± 0.1)
3 6 79.3±24.4 5.0± 1.0 454±224 27.5±4.5 8.2± 1.4
(54.1 ± 16.9) (0.8 ± 0.1) (32.2 ± 13.5) (22.4 ± 3.7) (0.6 ± 0.1)
12 5 32.1 ± 12.6 4.8 ± 1.1 436 ± 243 33.3 5.3 4.6 ± 1.0
(24.2 ± 9.8) (0.9 ± 0.2) (30.7 ± 17.5) (27.9 ± 4.4) (0.3 ± 0.1)
aEach value represents the mean ± SE.
bNumbers in parentheses representmg%O of administered DEHP.
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FIGURE 1. Concentration of DEHP or MEHP in tissues 1 hr. after
the oral administraiton of DEHP or MEHP to pregnant and non-
pregnant mice: (A) distribution of MEHP after the oral adminis-
traiton of MEHP; (B), (C) the distributions of MEHP and DEHP
respectively, after the oral administration ofDEHP. DEHP(10 mL/
kg) orMEHP(1 mL/lkg)wasgiven tothemiceandtheirconcentraiton
in various tissues and fluid 'vere determined by GLC. The analytical
procedure is as described in the Experimental section.
both phthalate intissues varied greatly dependingonthe
day of DEHP administration. The fluctuations were
greatest in the pancreas, in which the concentration of
both DEHP and MEHP were the highest among those
tissues examined. Averylowconcentrationwas observed
when DEHP was given on day 13 of gestation, though
the reason for this is not clear. As far as the fetuses are
concerned, the concentrations ofboth DEHP and MEHP
were the highest when administered to the mice on day
8 of their gestation. The above results might be corre-
lated to the high incidence ofteratogenic effects induced
by the administration of DEHP or MEHP on that day.
In the administration experiment of DEHP, there are
two possibilities to explain the presence of MEHP in
fetuses. One explanation is the hydrolysis of DEHP to
MEHP in the maternal body followed by the transfer of
MEHP across the placenta; the otheris direct hydrolysis
of DEHP to MEHP in the fetuses. In order to examine
the hydrolytic activity of the tissue of pregnant mice,
DEHP or ethyl palmitate was incubated at 37°C for 30
min with a homogenate ofpancreas, liver, or fetuses ob-
tained from pregnant mice ofvarying days ofgestation.
MEHP or palmitate formed in the above reaction was
determined as described in the Experimental section.
Figure 2 shows the results ofthe hydrolysis ofDEHP
to MEHP As expected, the pancreas showed the highest
activities among the three organs tested. The activity
varied greatly, depending on the day ofpregnancy. As it
is clear from Figure 2, no hydrolytic activity was de-
tected infetuses frommice on days 7, 8, or9 ofgestation.
Weak activity (0.01 ,u mole of MEHP/mg protein), was
detected in fetuses from mice of day 10 of gestation.
Similar activity changes were observed when ethyl pal-
mitate was used as a substrate; no activity was detected
with fetuses from 7th or 8th day pregnant mice. The
same weak activity (0.01 ,u mole ofpalmitic acid/mg pro-
tein) was detected in both fetuses from 9th or 10th day
pregnant mice (The hydrolytic activities of ethyl palmi-
tate ofthe pancreas and liver were 3.28-5.77 and 0.01-
0.11 ,u mole of palmitic acid/mg protein, respectively).
From the above experiment, it can be assumed that
MEHP found in the fetuses ofmice administered DEHP
(7th or 8th day of gestation) is of maternal origin. The
transplacental crossing ofMEHP into mouse fetuses has
already been demonstrated by GLC analysis. These find-
ings may further suggest that MEHP is the acting com-
pound which directly interacts with mouse fetuses to
produce the teratogenic effects. We have previously re-
ported that MEHP, not DEHP, showed mutagenic effects
in a variety ofassay systems (16). These systems include:
Rec assay using B. subtilis, reverse mutation test using
E. coli WP2 and S. typhimurium TA100, forward mu-
tation assay, and chromosome aberration test with V79
Chinese hamster cells and Syrian golden hamster em-
bryonic cells. Inadditiontothe abovefindings, theresults
of the spot test using inbred strains of mice (KYG, Y
x PW d or C57BL/6Crj 9 x PW d) should be noted.
0 7 8 9 10
Day of gestation
FIGURE 2. DEHP hydrolytic activity in maternal and fetal tissue of
pregnant mice: 0 represents a nonpregnant control, (0) pancreas,
(C) liver, (0) fetuses. Acyl hydrolase activity was determined with
Rhodamine 6G using mice tissue homogenates of various stages of
pregnancy The tissue homogenate was prepared with 4-fold 0.25
M sucrose solution and was incubated at 37°C for 30 min as de-
scribed in the Experiemental section.
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Table 4. Spot incidence in offspring of KYG or C57BL females mated with PW males, following injection with DEHP and MEHP
on day 10.5 after conception.
Surviving up to White spot Recessive spot
Treatment Dose, mg/kg No. born 4 weeks, % (WMVS), % (RS), %
DEHP 500 1298 93.8a 4. la 0.8a
(159)b (97.5)b (0.6)b (2.6)b
MEHP 25 159 96.9 1.3 2.6*
MEHP 50 172 95.3 1.2 3.7**
(117) (97.4) (0) (5.3)*
Control 500 97.4 1.6 0.4
(426) (99.8) (0.5) (0.9)
aNumbers represent the results from F1 of KYG x PW.
bNumbers in parentheses represent the results from F1 of C57BL/6NCrj x PW.
*p < 0.05.
**P < 0.01.
Table 4 summarizes the results. DEHP (500 mg/kg)
orMEHP (25, 50 mg/kg) wasinjected once intopregnant
mice after 10.5 days gestation. The survivingrate forthe
offspring up to 4 weeks and the appearance of white
midventral spots (WMVS) intreated groups, which prob-
ably resulted from killing ofmelanocyte precursor cells,
were not significantly different from those ofthe control
group (except in the case ofoffspring from KYG females
treated with DEHP). The appearance ofthe numbers of
recessive spots (RS) were significantly different in the
MEHP-treated groups. The present findings again sug-
gest that MEHP is more genotoxic than DEHP
Discussion
The effects of DEHP and MEHP on fetotoxicity and
on teratogenicity have been reviewed by Peakall (23),
Thomas et al. (24,25) and well summarized in the status
report on phthalate in consumer products (26).
We have reported in the previous paper that not only
DEHP but MEHP could produce feto- and teratotoxic
effects on pregnant mice (ddY, 9 x CBA, d) at suffi-
ciently high dosage (4,27).
The effects were closely related to the time and dose
for both DEHP and MEHP Treatment on day 7 of ges-
tation resulted in the early death of embryos/fetuses,
whereas on day 8 ofgestation, the treatment resulted in
later deaths. Moreover, the toxic effects were similar if
the results of 10 mL and 1 mL of DEHP and MEHP
were compared. The administration of either DEHP or
MEHP on day8 ofgestationresulted in both gross (47%,
100%) and skeletal (33%, 100%) abnormalities while on
day 9, gross abnormalities (21% for DEHP, 30% for
MEHP) were exclusively produced. Their effects on the
mortalities ofthe fetuses versus the day ofgestation are
also of the same pattern.
It follows that MEHP is probably responsible, at least
in part, for the fetotoxicity ofDEHP DEHP is known to
be metabolized to MEHP followed by w or w-1 oxidation
to produce a variety ofoxidation products in animals and
men (28-30). The hydrolysis of DEHP to MEHP is cat-
alyzed by pancreatic lipase (9) as well as by esterases of
serum (12), mucosal epitherium (10,11) and liver (6). The
datafromthepresentstudy on DEHPhydrolysis indicate
that the hydrolytic activities ofthe fetuses up to the 9th
day of gestation were almost negligible compared with
those ofthe pancreas and liver. Only a weak activity was
found for the fetuses of 10th day gestating mice. It is
assumed that the presence of MEHP in mouse fetuses
(0.3-0.6 mg-% ofDEHP administered, 1-12 hrafterthe
DEHP administration) in Table 2 is the result of tran-
splacental incorporation of MEHP which was formed in
maternal bodies. The possibility oftransplacental cross-
ing of MEHP is evident from Figure 1A. In Figure 1A-
C, a higher concentration of MEHP (and DEHP) was
observed in fetuses of 8th day pregnant mice compared
with those from other mice ofvarying days ofpregnancy
A less restrictive placental barrier may be possible in
8th day gestation mice.
The presence ofMEHP (or DEHP) in the fetuses may
indicate the embryotoxic/fetotoxic effects of MEHP (or
DEHP) though other indirect effects such as the meta-
bolic disturbance of maternal bodies could also be an
explanation for toxic effects on embryos/fetuses.
We previously reported that MEHP, but not DEHP,
showed mutagenic effects directly in bacteria and mam-
malian cell bioassay system. The effects ofMEHP on S.
typhimurrium TA100 disappeared when MEHP was
preincubated with rat liver S9 fraction. The metabolic
oxidation of MEHP molecule seems more likely to occur
in rats than in mice (30). Rapid metabolic oxidation of
MEHP to dicarboxylic acid in rats might prevent em-
bryos/fetuses from death or malformation: thus little or
less embryotoxic/fetotoxic effects have been observed in
more rats than in mice (31-33).
Finally, recessive spot incidences in somatic mutation
test with the offsprings of mice from two strains were
significantly induced by MEHP Although this is a pre-
liminary experiment, a genotoxic effect of MEHP has
been again demonstrated. It seems probable that higher
doses (> 500 mg/kg) of DEHP would produce a similar
effect in this test.
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